Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | F2 | P00734 | 1/20 | 0.74 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20802158 | 0.87 | F10 (0.83) | F10ABCB11F2ST14CYP1A2 | |
| SCHEMBL15203297 | 0.86 | F10 (0.79) | F10ABCB11F2ST14CYP1A2 | |
| Rivaroxaban SCHEMBL7721848 | 0.85 | F10 (1.00) | F10ABCB11F2ST14CYP1A2 | |
| Rivaroxaban SCHEMBL77766 | 0.85 | F10 (1.00) | F10ABCB11F2ST14CYP1A2 | |
| Rivaroxaban SCHEMBL3914 | 0.85 | F10 (1.00) | F10ABCB11F2ST14CYP1A2 | |
| Rivaroxaban SCHEMBL14796329 | 0.84 | F10 (0.98) | F10ABCB11F2ST14CYP1A2 | |
| SCHEMBL14838697 | 0.83 | F10 (0.82) | F10ABCB11F2ST14CYP1A2 | |
| SCHEMBL15180492 | 0.83 | F10 (0.81) | F10ABCB11F2ST14CYP1A2 | |
| SCHEMBL14838628 | 0.83 | F10 (0.81) | F10ABCB11F2ST14CYP1A2 | |
| SCHEMBL8082616 | 0.83 | F10 (0.79) | F10ABCB11F2ST14CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10040786-B2 | Process for preparing a polymorph of rivaroxaban | ZAKLADY FARMACEUTYCZNE POLPHAMRA SA (PL) | 2018-08-07 | — | — | US | disclosed |
| US-20180214453-A1 | RIVAROXABAN PHARMACEUTICAL COMPOSITIONS | INTERQUIM, S.A. (ES) | 2018-08-02 | — | — | US | disclosed |
| US-9938272-B2 | Hydrazine compound as blood coagulation factor Xa inhibitor | NORTH CHINA PHARMACEUTICAL COMPANY., LTD. (CN) | 2018-04-10 | — | — | US | disclosed |
| US-20170354723-A1 | COMPOSITIONS AND METHODS FOR CELL TRANSPLANTATION | PROMETHERA BIOSCIENCES S.A. (BE) | 2017-12-14 | — | — | US | disclosed |
| US-20170313689-A1 | PROCESS FOR PREPARING A POLYMORPH OF RIVAROXABAN | Zaklady Fammaceutyczne Polpharma SA (PL) | 2017-11-02 | — | — | US | disclosed |
| US-9775890-B2 | Factor Xa inhibitor used with liver-derived progenitor cells | Université Catholique de Louvain (BE) | 2017-10-03 | — | — | US | disclosed |
| US-20170152259-A1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR | NORTH CHINA PHARMACEUTICAL COMPANY., LTD. (CN) | 2017-06-01 | — | — | US | disclosed |
| US-9598403-B2 | Process for the preparation of rivaroxaban | AMNEAL PHARMACEUTICALS LLC (US) | 2017-03-21 | — | — | US | disclosed |
| US-20170049782-A1 | ACTIVE INGREDIENT (I) CONTAINING COMPOSITION AND METHOD FOR PREPARING SAME | SK CHEMICALS CO., LTD. (KR) | 2017-02-23 | — | — | US | disclosed |
| US-9562040-B2 | Processes for preparing Rivaroxaban | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-02-07 | — | — | US | disclosed |
| US-8466280-B2 | Co-crystal compound of rivaroxaban and malonic acid | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-18 | — | — | US | disclosed |
| US-20130005701-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-01-03 | — | — | US | disclosed |
| US-20120231076-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING RIVAROXABAN | RATIOPHARM GMBH (DE) | 2012-09-13 | — | — | US | disclosed |
| US-8106192-B2 | Method for producing 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20120009172-A1 | INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20110288294-A1 | Preparation process for an inhibitor of a blood clotting factor | ARCHIMICA GMBH (DE) | 2011-11-24 | — | — | US | disclosed |
| US-20110189279-A1 | PHARMACEUTICAL COMPOSITIONS WITH MODIFIED RELEASE PROPERTIES COMPRISING 5-CHLORO-N-(-METHYL)-2-THIOPHENCARBOXAMID | RATIOPHARM GMBH (DE) | 2011-08-04 | — | — | US | disclosed |
| US-20110152266-A1 | CO-CRYSTAL COMPOUND OF RIVAROXABAN AND MALONIC ACID | BAYER SCHERING PHARMA AG (DE) | 2011-06-23 | — | — | US | disclosed |
| US-7932278-B2 | 2-aminoethoxyacetic acid derivatives and their use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-26 | — | — | US | disclosed |
| US-20110033459-A1 | COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR | PORTOLA PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170354723-A1 | COMPOSITIONS AND METHODS FOR CELL TRANSPLANTATION | SERPINC1, F13B, F12 | F10 7/4885ABCB11 2263/4885F2 9/4885 |
| US-20120009172-A1 | INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR | P2RY12, P2RY11, P2RY13 | F10 192/4885ABCB11 368/4885F2 47/4885 |
| US-20130005701-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | F10 9/4885ABCB11 337/4885F2 1/4885 |
| US-20170152259-A1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR | F12, F10, F11 | F10 2/4885ABCB11 1751/4885F2 4/4885 |
| US-20110288294-A1 | Preparation process for an inhibitor of a blood clotting factor | TFPI, F5, F11 | F10 10/4885ABCB11 4009/4885F2 7/4885 |
| US-20120231076-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING RIVAROXABAN | VKORC1, VKORC1L1, F2 | F10 17/4885ABCB11 1627/4885F2 3/4885 |
| US-10040786-B2 | Process for preparing a polymorph of rivaroxaban | F2, VKORC1, VKORC1L1 | F10 17/4885ABCB11 1328/4885F2 1/4885 |
| US-20170049782-A1 | ACTIVE INGREDIENT (I) CONTAINING COMPOSITION AND METHOD FOR PREPARING SAME | MLN, SI, CYP3A5 | F10 1524/4885ABCB11 370/4885F2 597/4885 |
| US-20110152266-A1 | CO-CRYSTAL COMPOUND OF RIVAROXABAN AND MALONIC ACID | ME1, ME3, MAL2 | F10 55/4885ABCB11 4533/4885F2 86/4885 |
| US-20170313689-A1 | PROCESS FOR PREPARING A POLYMORPH OF RIVAROXABAN | F2, VKORC1, VKORC1L1 | F10 17/4885ABCB11 1328/4885F2 1/4885 |
| US-20110189279-A1 | PHARMACEUTICAL COMPOSITIONS WITH MODIFIED RELEASE PROPERTIES COMPRISING 5-CHLORO-N-(-METHYL)-2-THIOPHENCARBOXAMID | NT5C, HTR5A, NT5C3B | F10 4617/4885ABCB11 128/4885F2 4508/4885 |
| US-20180214453-A1 | RIVAROXABAN PHARMACEUTICAL COMPOSITIONS | F2, CACNA1A, SRSF6 | F10 36/4885ABCB11 1790/4885F2 1/4885 |
| US-20110033459-A1 | COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR | MPL, P2RY4, P2RY1 | F10 472/4885ABCB11 337/4885F2 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.